Skip to main content
Top
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Breast Cancer | Research article

The Will Rogers phenomenon, breast cancer and race

Authors: Mary R. Nittala, Eswar K. Mundra, S. Packianathan, Divyang Mehta, Maria L. Smith, William C. Woods, Shawn McKinney, Barbara S. Craft, Srinivasan Vijayakumar

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

The Will Rogers phenomenon [WRP] describes an apparent improvement in outcome for patients’ group due to tumor grade reclassification. Staging of cancers is important to select appropriate treatment and to estimate prognosis. The WRP has been described as one of the most important biases limiting the use of historical cohorts when comparing survival or treatment. The main purpose of this study is to assess whether the WRP exists with the move from the AJCC 7th to AJCC 8th edition in breast cancer [BC] staging, and if racial differences are manifested in the expression of the WRP.

Methods

This is a retrospective analysis of 300 BC women (2007–2017) at an academic medical center. Overall survival [OS] and disease-free survival [DFS] was estimated by Kaplan-Meier analysis. Bi and multi-variate Cox regression analyses was used to identify racial factors associated with outcomes.

Results

Our patient cohort included 30.3% Caucasians [Whites] and 69.7% African-Americans [Blacks]. Stages I, II, III, and IV were 46.2, 26.3, 23.1, and 4.4% of Whites; 28.7, 43.1, 24.4, and 3.8% of Blacks respectively, in anatomic staging (p = 0.043). In prognostic staging, 52.8, 18.7, 23, and 5.5% were Whites while 35, 17.2, 43.5, and 4.3% were Blacks, respectively (p = 0.011).
A total of Whites (45.05% vs. 47.85%) Blacks, upstaged. Whites (16.49% vs. 14.35%) Blacks, downstaged. The remaining, 38.46 and 37.79% patients had their stages unchanged.
With a median follow-up of 54 months, the Black patients showed better stage-by-stage 5-year OS rates using 8th edition compared to the 7th edition (p = 0.000). Among the Whites, those who were stage IIIA in the 7th but became stage IB in the 8th had a better prognosis than stages IIA and IIB in the 8th (p = 0.000). The 8th showed complex results (p = 0.176) compared to DFS estimated using the 7th edition (p = 0.004).

Conclusion

The WRP exists with significant variability in the move from the AJCC 7th to the 8th edition in BC staging (both White and Black patients). We suggest that caution needs to be exercised when results are compared across staging systems to account for the WRP in the interpretation of the data.
Literature
1.
go back to reference Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.CrossRef
2.
go back to reference Hassan A, Hussain F, Sohn C, et al. Early onset of breast carcinoma in African American women with poor prognostic factors. Am J Clin Onc. 1999;22:436.CrossRef Hassan A, Hussain F, Sohn C, et al. Early onset of breast carcinoma in African American women with poor prognostic factors. Am J Clin Onc. 1999;22:436.CrossRef
7.
go back to reference Gluliano AE, Connolly JL, Edge SB, Mittendorf EA, et al. Breast cancer- major changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:290–303.CrossRef Gluliano AE, Connolly JL, Edge SB, Mittendorf EA, et al. Breast cancer- major changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:290–303.CrossRef
8.
go back to reference Edge SB, Byrd DR, Compton CC, et al. The AJCC Cancer staging manual. 7th ed: Springer; 2009. p. 345–76. Edge SB, Byrd DR, Compton CC, et al. The AJCC Cancer staging manual. 7th ed: Springer; 2009. p. 345–76.
15.
go back to reference Kurundkar A, Gao X, Zhang K, Britt JP, et al. Comparison of AJCC anatomic and clinical prognostic stage groups in breast cancer: analysis of 3322 cases from a single institution. Clin Breast Cancer. 2018;18:1347–52.CrossRef Kurundkar A, Gao X, Zhang K, Britt JP, et al. Comparison of AJCC anatomic and clinical prognostic stage groups in breast cancer: analysis of 3322 cases from a single institution. Clin Breast Cancer. 2018;18:1347–52.CrossRef
18.
go back to reference Gradishar WJ, Anderson BO, Balassanian R, et al. NCCN Guidelines® insights breast cancer, version 1.2017: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2017;15:433–51.CrossRef Gradishar WJ, Anderson BO, Balassanian R, et al. NCCN Guidelines® insights breast cancer, version 1.2017: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2017;15:433–51.CrossRef
19.
go back to reference Plichta JK, Ren Y, Thomas SM, et al. Implications for breast cancer restaging based on the 8th edition AJCC staging manual. Ann Surg. 2018;271(1):169–76.CrossRef Plichta JK, Ren Y, Thomas SM, et al. Implications for breast cancer restaging based on the 8th edition AJCC staging manual. Ann Surg. 2018;271(1):169–76.CrossRef
23.
go back to reference Gofrit ON, Zorn KC, Steinberg GD, et al. The will Rogers phenomenon in urological oncology. J Urol. 2007;179:28–33.CrossRef Gofrit ON, Zorn KC, Steinberg GD, et al. The will Rogers phenomenon in urological oncology. J Urol. 2007;179:28–33.CrossRef
25.
go back to reference Vijayakumar S, Vaida F, Weichselbaum R, et al. Race and the will Rogers phenomenon in prostate cancer. Cancer J Sci Am. 1998;4:27–34.PubMed Vijayakumar S, Vaida F, Weichselbaum R, et al. Race and the will Rogers phenomenon in prostate cancer. Cancer J Sci Am. 1998;4:27–34.PubMed
26.
go back to reference Jani AB, Vaida F, Hanks G, Asbell S, Sartor O, Moul JW, et al. Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. Int J Cancer. 2001;96(6):363–71. https://doi.org/10.1002/ijc.1035.CrossRefPubMed Jani AB, Vaida F, Hanks G, Asbell S, Sartor O, Moul JW, et al. Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. Int J Cancer. 2001;96(6):363–71. https://​doi.​org/​10.​1002/​ijc.​1035.CrossRefPubMed
29.
go back to reference Damaris C. The Will Rogers phenomenon. Roping the effects of a new cancer staging system. J Natl Cancer Inst. 2013;95:1105–6. Damaris C. The Will Rogers phenomenon. Roping the effects of a new cancer staging system. J Natl Cancer Inst. 2013;95:1105–6.
35.
go back to reference Wong RX, Wong FX, Lim J, et al. Validation of the AJCC 8th prognostic system for breast cancer in an Asian health care settings. Breast. 2018;4:0960–9776. Wong RX, Wong FX, Lim J, et al. Validation of the AJCC 8th prognostic system for breast cancer in an Asian health care settings. Breast. 2018;4:0960–9776.
Metadata
Title
The Will Rogers phenomenon, breast cancer and race
Authors
Mary R. Nittala
Eswar K. Mundra
S. Packianathan
Divyang Mehta
Maria L. Smith
William C. Woods
Shawn McKinney
Barbara S. Craft
Srinivasan Vijayakumar
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-08125-8

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine